Bristol-Myers Squibb Company (BMY) Cash Flow Statement

The wide dispersion in the OCF-to-net-income ratio suggests that quarterly net income is distorted by large amortization of acquired intangibles and milestone or alliance accounting rather than by operating cash generation. A ratio above 2.0 in several quarters implies that cash generation has been materially stronger than the GAAP earnings line would indicate. Investors should monitor whether this gap reflects durable cash economics or simply the timing of working capital releases that may reverse.

Such large two-directional working capital movements suggest sensitivity to channel inventory timing, year-end wholesaler dynamics, and collection cycles on high-value biologics. The sequence of a large inflow followed by a large outflow may point to the reversal of year-end collections rather than a structural improvement. Analysts should treat single-quarter operating cash flow with caution and focus on trailing trends.

Capital expenditures remain small at roughly 2.3% to 3.0% of revenue, so the swings in free cash flow are almost entirely attributable to operating cash flow variability. The trailing average suggests a healthier underlying cash profile than the lowest quarters imply, though the trend remains uneven. Investors should weigh whether recent strength can be sustained as legacy product revenue erodes.

A consistent quarterly dividend near $1.3B represents a fixed claim on cash that must be covered by operating cash flow, which appears adequate in most quarters but thin in 2026Q1. The absence of buybacks combined with sizable acquisition outflows suggests capital is being redirected toward pipeline acquisitions rather than returned in excess. The sustainability of this payout depends on whether new launches can offset erosion in legacy revenue.